A personalised taper-to-target strategy with adalimumab in Crohn's disease
- PMID: 36736340
- DOI: 10.1016/S2468-1253(23)00009-2
A personalised taper-to-target strategy with adalimumab in Crohn's disease
Conflict of interest statement
BV reports financial support for research from AbbVie, Biora Therapeutics, Pfizer, Sossei Heptares, and Takeda; lecture fees from AbbVie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion, and Viatris; and consultancy fees from AbbVie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Mylan, Inotrem, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, Takeda, Tillots Pharma, and Viatris. ED received consultancy fees from Alimentiv and Argenx, lecture fees from Galapagos, and financial support from Janssen (2022) and Prometheus; all honoraria and fees were paid to his university. BV is supported by the Clinical Research Fund (KOOR) at the University Hospitals Leuven and the Research Council at KU Leuven.
Comment on
-
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.Lancet Gastroenterol Hepatol. 2023 Apr;8(4):343-355. doi: 10.1016/S2468-1253(22)00434-4. Epub 2023 Jan 31. Lancet Gastroenterol Hepatol. 2023. PMID: 36736339 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
